Exenatide, dapagliflozin or phentermine/topiramate differentially affect metabolic profiles in polycystic ovary syndrome

CONCLUSION: Dual therapy with EQW/DAPA was superior to either alone, DAPA/MET and PHEN/TPM in terms of clinical and metabolic benefits in this patient population.PMID:34097062 | DOI:10.1210/clinem/dgab408

Source: The Journal of Clinical Endocrinology and Metabolism - June 7, 2021 Category: Endocrinology Authors: Karen E Elkind-Hirsch N Chappell Ericka Seidemann John Storment Drake Bellanger Source Type: research